Tuesday, 21 May 2019

You are here

Early TNF inhibition in Early Psoriatic Arthritis

Early and aggressive DMARD therapy is ideal for most patients with inflammatory disorders. A small, double-blind, randomised, placebo-controlled trial in early psoriatic arthritis (PsA) has shown that first-line use of golimumab and methotrexate (MTX) is superior to MTX alone in inducing remission in PsA.

They conducted an investigator-initiated, multicentre, double-blind, randomised, placebo-controlled trial, enrolling 51 PsA patients who were MTX and bDMARD-naive (fulfilling the CASPAR criteria) and had active disease at baseline (≥3 swollen joint count/tender joint count). The primary endpoint was the number achieving Disease Activity Score (DAS) remission (<1.6) at week 22. 

These patients had on average 6 mos duration for their arthritis and 6-11 yrs duration for their psoriasis.  The baseline DAS28-CRP was  a mean of 2.4 and they had an average of 10 tender joints and 5-7 swollen joints at entry.

At week 22, DAS < 1.6 (remission) was achieved by 81% in the TNFi+MTX arm versus 42 % in the MTX only arm (p=0.004). 

The difference was evident at week 8. At week 22 other secondary responses were significantly better including MDA, ACR20/50/70, disease measures and patient-reported outcomes.

Adverse events were similar in both arms. 

Early initiation of TNFi appears to be highly effective in early PsA patients.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Low Serious Infection Risk with Newer Agents in Psoriasis

JAMA Dermatology reports on a comparative cohort study of 107,707 psoriasis patients, finding a decreased risk of serious infections among users of apremilast, etanercept, and ustekinumab when compared with methotrexate.

Skyrizi (risankizumab) FDA Approved for Psoriasis

AbbVie has announced that the US FDA has granted the approval of Skyrizi (risankizumab-rzaa) for the treatment of moderate to severe plaque psoriasis. 

Skyrizi is an interleukin-23 (IL-23) inhibitor that was also recently approved in Canada and Japan. Skyrizi is the third IL-23 inhibitor (behind guselkumab [Tremfya] and tildrakizumab [Ilumya]) to be approved in the last year.

Higher Comorbidities in Hidradenitis Suppurativa

JAMA Dermatology reports that patients with hidradenitis suppurativa have significantly more comorbidities than do patients with psoriasis.

A cross-sectional study compared 5306 HS patients, 14 037 patients with psoriasis, and 1 733 810 controls from electronic health records between 2013 and 2018. Specifically they examined comorbidities using the Charlson Comorbidity Index (CCI) score.

Biologic Agents have Equal Efficacy in Enthesitis and Dactylitis

A systematic review has shown that TNF inhibitors (TNFi) are equaled in efficacy by other biologic agents (ustekinumab, secukinumab, and ixekizumab) in psoriatic arthritis (PsA) patients with in dactylitis and enthesitis.

The literature review analyzed datafrom randomized controlled trials (RCTs) with TNFi (infliximab, golimumab, adalimumab), antiinterleukin- 12/23 (ustekinumab) and anti-interleukin-17 (secukinumab, ixekizumab).

Dual IL-17 Inhibitor in Psoriasis Succeeds

Patients with moderate-to-severe plaque psoriasis attained durable complete and near-complete responses for more than a year with a dual inhibitor of interleukin (IL)-17, data from a randomized trial showed.